Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Prospektiv Randomiseret Evaluering og Behandling af For tidlig Aterosklerose (PRE-EMPT) (PRE-EMPT)

6. november 2026 opdateret af: Duke University

Prospektiv Randomiseret Evaluering og Behandling af For tidlig Aterosklerose

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.

PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:

  1. A Screening Study - Participants will be assessed for plaque by one or both of these scans.

    • Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
    • Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
  2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.

    • Rosuvastatin 20 mg: a cholesterol-lowering medicine
    • Colchicine 0.5 mg: a medication that lowers inflammation

Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.

Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

1500

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35205
        • Rekruttering
        • University of Alabama at Birmingham
        • Ledende efterforsker:
          • Kevin Riggs, MD
        • Kontakt:
      • Mobile, Alabama, Forenede Stater, 36608
        • Rekruttering
        • Cardiology Associates
        • Kontakt:
        • Ledende efterforsker:
          • Jason Cole, MD
    • California
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • University of California, Los Angeles
        • Kontakt:
        • Ledende efterforsker:
          • Karol Watson, MD
      • Los Angeles, California, Forenede Stater, 90502
        • Rekruttering
        • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Matthew Budoff, MD
    • Georgia
      • Hiram, Georgia, Forenede Stater, 30141
        • Rekruttering
        • Wellstar Kennestone Hospital
        • Ledende efterforsker:
          • Frank Corrigan, MD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • University of Chicago
        • Ledende efterforsker:
          • Tamar Polonsky, MD
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Ikke rekrutterer endnu
        • Johns Hopkins University
        • Kontakt:
        • Ledende efterforsker:
          • Michael Blaha, MD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital Brigham
        • Kontakt:
        • Ledende efterforsker:
          • Michael Honigberg, MD
    • Minnesota
      • Duluth, Minnesota, Forenede Stater, 55805
    • New York
      • Mount Kisco, New York, Forenede Stater, 10549
        • Ikke rekrutterer endnu
        • Northern Westchester Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Dina Katz, MD
      • New York, New York, Forenede Stater, 10021
        • Rekruttering
        • Weill Cornell Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Sam Kim, MD
      • New York, New York, Forenede Stater, 10016
        • Rekruttering
        • New York University Langone
        • Ledende efterforsker:
          • Harmony Reynolds, MD
        • Kontakt:
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Hospital
        • Ledende efterforsker:
          • Nishant Shah, MD
        • Kontakt:
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Rekruttering
        • Wake Forest University, Advocate Health
        • Ledende efterforsker:
          • Michael Shapiro, MD
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Ikke rekrutterer endnu
        • Oregon Health and Sciences University
        • Kontakt:
        • Ledende efterforsker:
          • Maros Ferencik, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Ikke rekrutterer endnu
        • Thomas Jefferson University
        • Kontakt:
        • Ledende efterforsker:
          • Chris Chambers, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Ledende efterforsker:
          • Anum Saeed, MD
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Rekruttering
        • Medical University of South Carolina (MUSC)
        • Ledende efterforsker:
          • Sheldon Litwin, MD
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Ikke rekrutterer endnu
        • Vanderbilt University
        • Ledende efterforsker:
          • Deepak Gupta, MD
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Houston Methodist Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Khurrrram Nasir, MD
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22903
        • Rekruttering
        • University of Virginia (UVA)
        • Kontakt:
        • Ledende efterforsker:
          • Todd Villines, MD
      • Fairfax, Virginia, Forenede Stater, 22031
        • Ikke rekrutterer endnu
        • Inova Health System
        • Kontakt:
        • Ledende efterforsker:
          • Jared Spitz, MD
    • Wisconsin
      • Marshfield, Wisconsin, Forenede Stater, 54449
        • Rekruttering
        • Marshfield Clinical Research Institute
        • Kontakt:
        • Ledende efterforsker:
          • Jeff VanWormer

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

30 år til 60 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Women aged 40-60 years; Men aged 30-50 years
  2. Willing and able to provide informed consent and comply with study procedures
  3. Smart phone user
  4. Use of highly effective contraception by females with reproductive potential.
  5. CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
  6. Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab

Exclusion Criteria:

  1. Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
  2. Current symptoms thought to be from CAD
  3. PREVENT ASCVD 10-year risk ≥5% (if known)
  4. Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
  5. LDL-C ≥190mg/dL (most recent, if known)
  6. HIV (if known)
  7. Severe liver disease or untreated Hepatitis C infection (if known)
  8. Pregnancy, lactation or intending to become pregnant during the study period of 2 years
  9. eGFR <45mL/min/1.73m2 (if known)
  10. AST or ALT >1.5x the upper limit of normal (if known)
  11. BMI>40kg/m2 or unable to have a CCTA scan for any reason
  12. Allergy to iodinated intravenous contrast or other contraindication to CCTA
  13. Current or previous use of lipid lowering therapy or colchicine
  14. Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
  15. Systemic cancer undergoing active treatment
  16. PREVENT ASCVD 10-year risk ≥5%
  17. eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
  18. Hemoglobin A1c ≥6.5% per baseline labs
  19. LDL-C ≥190mg/dL per baseline labs
  20. Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
  21. Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
  22. Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Faktoriel opgave
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: rosuvastatin 20mg plus colchicine-matched placebo

statin plus placebo (two pills once daily)

Statin

Andre navne:
  • Crestor

Placebo, non-active, drug-matched

Eksperimentel: colchicine 0.5mg plus rosuvastatin-matched placebo

anti-inflammatory plus placebo (two pills once daily)

Placebo, non-active, drug-matched

Anti-inflammatory

Andre navne:
  • Lodoco
Eksperimentel: rosuvastatin 20mg plus colchicine 0.5mg

statin plus anti-inflammatory (two pills once daily)

Statin

Andre navne:
  • Crestor

Anti-inflammatory

Andre navne:
  • Lodoco
Placebo komparator: placebo plus placebo

Placebo and placebo (two pills once daily)

Placebo, non-active, drug-matched

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Tidsramme: 2 years

Plaque volume in mm3 in each group

2 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring i LDL-C (low-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
Baseline til 2 år
Ændring i ikke-HDL-kolesterol (high-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
Baseline til 2 år
Number of participants with Drug Discontinuation
Tidsramme: Up to 2 years

Drug Tolerability outcome

Up to 2 years
Overall drug treatment adherence
Tidsramme: Up to 2 years

Number of days on study drugs

Up to 2 years
Safety events of special interest
Tidsramme: Up to 2 years

Number of safety events of special interest per group

Up to 2 years
Total plaque volume
Tidsramme: Up to 2 years

Plaque volume in mm3 per group

Up to 2 years
Low-attenuation plaque volume
Tidsramme: Up to 2 years

Low attenuated plaque volume in mm3 per group

Up to 2 years
Calcified plaque volume
Tidsramme: Up to 2 years

Calcified plaque volume in mm3 per group

Up to 2 years
Number of participants with stenosis
Tidsramme: Up to 2 years

Number of participants with stenosis per group

Up to 2 years
Segment involvement score
Tidsramme: Up to 2 years

Average score per group

Up to 2 years
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Tidsramme: Up to 2 years

Number of participants with each plaque composition description per group

Up to 2 years
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Tidsramme: Up to 2 years

Number of participants with each plaque feature (high-risk) per group

Up to 2 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

21. juli 2026

Primær færdiggørelse (Anslået)

1. juli 2031

Studieafslutning (Anslået)

1. juli 2031

Datoer for studieregistrering

Først indsendt

14. november 2025

Først indsendt, der opfyldte QC-kriterier

14. november 2025

Først opslået (Faktiske)

18. november 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • Pro00118744
  • UG3HL181434 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .